A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years

NCT00909961 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG: Zoledronic acid

Sponsor

Novartis Pharmaceuticals